INS-HEALTH PLAN BENEFIT DATA
SB0229 amends the Illinois Insurance Code to require health plans and pharmacy benefit managers operating in Illinois to provide patient-specific prescription cost, benefit, and coverage information upon request. The bill applies when the request is made by a covered individual, the individual’s health care provider, or an authorized third party, and it requires the information to be current within one business day of any change, available in real time, and delivered in an accessible electronic format. For providers, the data must be usable through electronic health record systems, and the request must use recognized industry content and transport standards rather than fax.
The bill also requires disclosure of detailed drug-specific information for any covered medication, including eligibility, formulary and cost-sharing data, clinically appropriate alternatives, lower-cost treatment options, and utilization management requirements. It prohibits health plans and PBMs from blocking, delaying, or discouraging access to this information, from restricting prescribers from discussing lower-cost or cash-price options, and from requiring patients to use plan-preferred drugs or pharmacies through real-time benefit tools. The stated effective deadline for compliance is July 1, 2026.
If enacted, SB0229 would create new sections 356z.80 and 513b8 in the Illinois Insurance Code and impose new transparency obligations on both health plans and pharmacy benefit managers. It would expand patient and prescriber access to real-time prescription pricing and coverage data, standardize the format of electronic requests, and limit practices that could impede sharing of benefit information. The bill would affect insurers, PBMs, prescribers, patients, and third-party entities acting on a patient’s behalf, while also shaping how electronic prescribing and real-time benefit tools operate in the state.
Based on the bill text and the absence of recorded committee testimony or votes, the measure appears to be framed as a consumer- and provider-friendly transparency bill. Its overall tone is pro-disclosure and pro-access, emphasizing timely information, patient choice, and the ability of clinicians to discuss lower-cost alternatives. No formal opposition or support is documented in the provided materials, but the structure of the bill suggests it is intended to address concerns about opaque prescription pricing and coverage information.
The main points of potential contention are likely to involve compliance burdens on health plans and PBMs, the technical requirements for real-time data exchange, and the bill’s restrictions on practices that could steer patients toward plan-preferred drugs or pharmacies. Insurers and PBMs may object to the operational costs of maintaining one-business-day updates, integrating with electronic health records, and responding in standardized formats. On the other side, patient advocates and prescribers would likely support the bill’s limits on delays, fees, and interference with communication about cash prices, lower-cost alternatives, and support programs.